Catalyst’s approach builds on the company’s unique protease engineering platform, which can generate improved or novel molecules to help correct disease-causing imbalances in the complement ...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) ...

Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 ...

Caseinolytic protease P (ClpP) is a conserved serine protease present in both bacteria and humans, essential for maintaining protein quality by degrading misfolded proteins.

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

Then protease enzymes in your stomach break down ... OK, so our bodies are constantly working without us even knowing about it. That's amazing. Miss Armit: That, Cel, is the wonder of the human ...

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immuno ...